SHARI TOMASETTI: Open Payments
NPI 1972717973 · BOSTON, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,307 in 153 payments from 31 companies in 2025. Trend: 2023 $2,661 · 2024 $3,566 · 2025 $3,307
Food & beverage: $3,239Education: $68
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 16 | $339 |
| Novo Nordisk Inc | 13 | $310 |
| Lilly USA, LLC | 12 | $302 |
| Insulet Corporation | 20 | $273 |
| Xeris Pharmaceuticals, Inc. | 13 | $254 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 9 | $204 |
| Bayer Healthcare Pharmaceuticals Inc. | 11 | $197 |
| Astellas Pharma US Inc | 6 | $176 |
| TOLMAR, INC. | 7 | $161 |
| ABBVIE INC. | 7 | $155 |
Products named: JARDIANCE, Omnipod, Ozempic, Kerendia, JATENZO, RECORLEV, EVENITY, SYNTHROID.
Industry payments across MA — which companies pay providers there.
